<--- Back to Details
First PageDocument Content
Rheumatologists / Autoimmune diseases / Michael D. Lockshin / Hospital for Special Surgery / Antiphospholipid syndrome / Systemic lupus erythematosus / Doruk Erkan / Specialty / Weill Cornell Medical College of Cornell University / Medicine / Health / Rheumatology
Date: 2011-12-19 13:48:22
Rheumatologists
Autoimmune diseases
Michael D. Lockshin
Hospital for Special Surgery
Antiphospholipid syndrome
Systemic lupus erythematosus
Doruk Erkan
Specialty
Weill Cornell Medical College of Cornell University
Medicine
Health
Rheumatology

Hospital for Special Surgery 535 East 70th Street New York, NY[removed]1000 www.hss.edu

Add to Reading List

Source URL: www.hss.edu

Download Document from Source Website

File Size: 1,80 MB

Share Document on Facebook

Similar Documents

ADVANCES IN RHEUMATOLOGY Affiliated with Columbia University College of Physicians and Surgeons and Weill Cornell Medical College NOVEMBER/DECEMBER 2014 The rheumatology program at NewYorkPresbyterian Hospital is compris

ADVANCES IN RHEUMATOLOGY Affiliated with Columbia University College of Physicians and Surgeons and Weill Cornell Medical College NOVEMBER/DECEMBER 2014 The rheumatology program at NewYorkPresbyterian Hospital is compris

DocID: 1fzzx - View Document

Presentation of Navigare Patient Flow and Positioning Product Group: Biological Drugs Target Groups: Rheumatologists Dermatologists Gastroenterologists Countries:

Presentation of Navigare Patient Flow and Positioning Product Group: Biological Drugs Target Groups: Rheumatologists Dermatologists Gastroenterologists Countries:

DocID: 1eAsN - View Document

Developed in Partnership with Rheumatologists Raintree Delivers EMR and Practice Management in a Single Software Solution

Developed in Partnership with Rheumatologists Raintree Delivers EMR and Practice Management in a Single Software Solution

DocID: 1d2Up - View Document

Important Safety Information for Rheumatologists About Risks in Patients Receiving ACTEMRA® ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist that has been approved by the Food and Drug Administrati

Important Safety Information for Rheumatologists About Risks in Patients Receiving ACTEMRA® ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist that has been approved by the Food and Drug Administrati

DocID: 1bTad - View Document

542  CONCISE REPORT Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials

542 CONCISE REPORT Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials

DocID: 1anTs - View Document